-

FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will be presenting at the 2023 RBC Capital Markets Private Company Conference. The virtual presentation will take place on Thursday, December 14, 2023, from 8:00-8:30 a.m. ET.

Shawn M. Leland, PharmD, RPh, Interim Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your RBC Capital Markets salesperson or Argot Partners to schedule one-on-one meetings with the management team.

About Fore Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients. Its lead asset plixorafenib (FORE8394; PLX8394) is a Class 1/V600 and 2 BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.

Contacts

Investors and Media:
Argot Partners
212.600.1902|ForeBio@argotpartners.com

Industry:

FORE Biotherapeutics

Release Versions
English

Contacts

Investors and Media:
Argot Partners
212.600.1902|ForeBio@argotpartners.com

More News From FORE Biotherapeutics

FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced that the Company will participate at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference. The Company will attend and participate in one-on-one meetings on Tuesday, September 8. Morgan Stanley 24th Annual Global Healthcare Conference. The Company will attend on Tuesday, September 15, and will provide a corporate presentation at 7:45 a.m. ET. Management will host and participate in one-on-one meetin...

FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that following the first of two pre-specified interim efficacy analyses for the FORTE basket study evaluating plixorafenib as a monotherapy in patients with advanced solid tumors with BRAF fusions, including recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, the Independent Data Monit...

FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced the closing of an upsized Series D-2 extension financing of $67.4 million, bringing the total Series D-2 amount raised to $110 million. The financing was co-led by SR One, Medicxi, and SymBiosis and supported by a syndicate of new investors, including TaiAx, LG Technology Ventures, Primer Ventures and Axil, and all existing i...
Back to Newsroom